Date: 2019-01-15

Type of information: Nomination

Compound: chief medical officer

Company: Voyager Therapeutics (USA-MA)

Therapeutic area: Neurological diseases - Neurodegenerative diseases

Type agreement: nomination

Action mechanism:



  • • On January 15, 2019, Voyager Therapeutics announced the appointment of Omar Khwaja, M.D., Ph.D., as chief medical officer. Dr. Khwaja’s background includes extensive research, translational, and clinical therapeutic development experience in neuroscience, neurogenetics and rare disease in both industry and academic roles. Dr. Khwaja is joining Voyager from Roche where he most recently served as Global Head of Neuroscience Translational Medicine and Global Head of Rare Diseases.
  • During his seven years at Roche, Dr. Khwaja established an integrated discovery and development rare disease unit with clinical development in neuroscience. Within these groups, Dr. Khwaja led the initiation of Roche’s first clinical programs in gene therapy and delivered into pivotal trials multiple programs across various therapeutic modalities and indications including spinal muscular atrophy (SMA) and Huntington’s disease.
  • Before joining Roche, Dr. Khwaja was Director of the Clinical Neurogenetics Program at Boston Children’s Hospital and on the faculty of Harvard Medical School. Dr. Khwaja received his M.D. and Ph.D. from the University of Cambridge, Cambridge, UK. He trained in pediatrics and clinical genetics in London, UK and Melbourne, Australia and completed his neurology training at Massachusetts General Hospital and Boston Children’s Hospital, where he was Chief Resident. He is a Member of the Royal Colleges of Physicians of the United Kingdom and a Member of the Royal College of Pediatrics and Child Health.

Financial terms:

Latest news:

Is general: Yes